Spyre Therapeutics, Inc.
NASDAQ:SYREBiotechnology
Healthcare
$97.63 +1.38%
+$1.21 today
- Market cap
- $9.27B
- Beta
- 3.06
- P/E (TTM)
- -171.1
- EPS (TTM)
- -$0.52
52W Low $14.00High $91.04
Volume 0.63M
Average 1.17M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$169.25M
FY 2025 · Annual
Investing Cash Flow
-$143.47M
FY 2025 · Annual
Financing Cash Flow
$309.02M
FY 2025 · Annual
-24.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (65.8M) | (83.82M) | (338.79M) | (208.02M) | (155.2M) |
| Depreciation & Amortization | 1.58M | 1.96M | 744K | 0 | 10M |
| Deferred Income Tax | 0 | (327K) | 0 | 0 | 0 |
| Stock-Based Compensation | 8.04M | 7.11M | 25.68M | 44.83M | 37.61M |
| Change in Working Capital | 1.83M | (5.5M) | (5.21M) | (4.53M) | (5.93M) |
| Accounts Receivables | (815K) | 440K | 375K | 0 | 0 |
| Inventory | 0 | (440K) | 0 | 0 | 0 |
| Accounts Payables | 1.07M | (2.64M) | 218K | (230K) | 7.65M |
| Other Working Capital | 1.58M | (2.86M) | (5.8M) | (4.3M) | (13.58M) |
| Other Non-Cash Items | 638K | 426K | 217.67M | 10.31M | (55.73M) |
| Operating Cash Flow | (53.72M) | (80.14M) | (99.91M) | (157.41M) | (169.25M) |
| Capital Expenditures | (573K) | (38K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 3.04M | 0 | 0 |
| Purchases of Investments | (133.08M) | (39.5M) | (166.8M) | (599.25M) | (522.21M) |
| Sales of Investments | 111.03M | 96.55M | 39.9M | 245.97M | 371.74M |
| Other Investing Activities | 0 | 0 | 15.48M | 0 | 7M |
| Investing Cash Flow | (22.62M) | 57.01M | (108.39M) | (353.29M) | (143.48M) |
| Debt Repayment | (510K) | (418K) | (16K) | 0 | 0 |
| Common Stock Issued | 0 | 42.87M | 169.11M | 236.38M | 314.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.9M | 222K | (5.38M) | 5.67M | (5.41M) |
| Financing Cash Flow | 1.39M | 42.68M | 361.08M | 410.91M | 309.03M |
| Effect of Forex Changes | (15K) | (106K) | 25K | (3K) | 0 |
| Net Change in Cash | (74.96M) | 19.44M | 152.8M | (99.79M) | (3.7M) |
| Free Cash Flow | (54.29M) | (80.18M) | (99.91M) | (157.41M) | (169.25M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$155.2M
+ D&A$10.0M
+ Stock-Based Comp$37.6M
+ Deferred Tax$0
- Working Capital-$5.9M
- Other Non-Cash-$55.7M
= Operating Cash Flow-$169.3M
- Capex$0
= Free Cash Flow-$169.3M
Analysis
FY2025 free cash flow is -$169.3M. FCF conversion is 109.1% of net income. Operating cash flow was -$169.3M, with capex of $0. The largest bridge item is Other Non-Cash at -$55.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 9, 2026 | |
| 8-K | Current report | Oct 7, 2026 | |
| 424B5 | 424B5 filing | Oct 6, 2026 |
Does SYRE generate free cash flow?
Spyre Therapeutics, Inc. (SYRE) generated -$169.25M of free cash flow in fiscal 2025.
How much operating cash flow does SYRE produce?
Operating cash flow was -$169.25M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.